Health Care • Misc Health and Biotechnology Services
$193.31 ▲ +9.38
(+5.10%)
MKT CAP: $12.33B • VOL: 2.08M
52W L $101 52W H $247
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$162
MEDIAN
$217
MEAN
$220
HIGH
$263
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE DVA TAPE
DVA // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $233.91 | $222.31 | 2025-02-14 | $175.91 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $243.57 | $228.11 | 2025-02-06 | $181.71 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $220.37 | $212.64 | 2025-01-29 | $185.58 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $197.18 | — | 2025-01-17 | $189.44 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $170.11 | $183.64 | 2025-01-09 | $172.05 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $230.04 | $201.04 | 2024-12-18 | $168.18 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $187.51 | $195.24 | 2024-12-04 | $179.78 | -4.3% | 48% | C |